mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line

Inclusion Criteria: * 20 years and older * pathologically confirmed biliary tract cancer (adenocarcinoma) including intrahepatic, extrahepatic, gallbladder, ampulla of vater * initially inoperable or recurrent * ECOG 0-2 * as first line chemotherapy, refractory to gemcitabine/cisplatin (at least one cycle applied) * evaluable or measurable lesion * within 1 week, patients who meet below laboratory results (hemoglobin \>9.0 g/dL, neutrophil \>1000/uL, platelet\> 75000/uL, serum creatinine \< UNL \* 1.5, AST/ALT \< UNL\*3, total bilirubin \< UNL\*1.5 (available for biliary drainage) * patients who have ability to understand the purpose, benefit and harm for this trial, and the right to withdraw this trial in any time without any disadvantage Exclusion Criteria: * other cancer history * pregnant or lactating * uncontrolled medical condition such as infection or cardiovascular disease * hypersensitivity to experimental drugs * uncontrolled CNS metastasis, psychologic problem